ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
1-Year Return
11.37%
This Quarter Return
-3.61%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$6.41B
AUM Growth
-$663M
(-9.4%)
Cap. Flow
-$178M
Cap. Flow
% of AUM
-2.77%
Top 10 Holdings %
Top 10 Hldgs %
73.95%
Holding
40
New
1
Increased
13
Reduced
7
Closed
7
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$236M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$58.2M |
| 3 |
Merus
MRUS
|
+$36.8M |
| 4 |
Kymera Therapeutics
KYMR
|
+$35.9M |
| 5 |
Krystal Biotech
KRYS
|
+$18.4M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$320M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$96.1M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
+$30.1M |
| 4 |
United Therapeutics
UTHR
|
+$26.3M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$25.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Tourmaline Bio
TRML
$1.22B
| $36.9M | 0.58% |
2,425,000
+202,778
| +9% | +$3.08M |
|
27
Ultragenyx Pharmaceutical
RARE
$2.96B
| $30.1M | 0.47% |
830,000
| – | – |
|
28
Taysha Gene Therapies
TSHA
$865M
| $27.8M | 0.43% |
19,999,999
| – | – |
|
29
uniQure
QURE
$923M
| $23.1M | 0.36% |
2,175,000
| – | – |
|
30
Monte Rosa Therapeutics
GLUE
$298M
| $21.6M | 0.34% |
4,645,548
+300,548
| +7% | +$1.39M |
|
|
AUTL
31
Autolus Therapeutics
AUTL
$375M
| $15.4M | 0.24% |
9,910,642
| – | – |
|
|
SEPN
32
Septerna, Inc. Common Stock
SEPN
$639M
| $7.74M | 0.12% |
1,337,500
+227,500
| +20% | +$1.32M |
|
|
WHWK
33
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$93.3M
| $5.07M | 0.08% |
2,849,402
| – | – |
|
|
34
BioMarin Pharmaceuticals
BMRN
$10.5B
| – | – |
-1,462,500
| Closed | -$96.1M |
|
35
CG Oncology
CGON
$2.57B
| – | – |
-700,000
| Closed | -$20.1M |
|
|
36
Iovance Biotherapeutics
IOVA
$850M
| – | – |
-3,500,000
| Closed | -$25.9M |
|
37
Kura Oncology
KURA
$729M
| – | – |
-2,250,000
| Closed | -$19.6M |
|
38
Olema Pharmaceuticals
OLMA
$553M
| – | – |
-1,651,982
| Closed | -$9.63M |
|
39
Rocket Pharmaceuticals
RCKT
$347M
| – | – |
-1,200,000
| Closed | -$15.1M |
|
|
40
Syndax Pharmaceuticals
SNDX
$1.39B
| – | – |
-2,275,000
| Closed | -$30.1M |
|